Dear Colleague,

The Journal of Opioid Management is pleased to offer the sixth annual International Conference On Opioids, June 11-13, 2017, at the Joseph B. Martin Conference Center at Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts. We are confident that your participation in this significant event will prove invaluable in your practice as it relates to the use of opioids for your patients.

An evidence-based educational conference is planned which will provide cutting-edge research and the latest in clinical best practices of opioids to improve patient outcomes. As the paradigm continues to evolve the new normal will be discussed with a look to the future of opioid prescribing including its challenges and solutions. We are guided by a dedicated conference committee and joined by renowned specialists in basic science, clinical application, compliance and the legal aspects to present this unique forum.

The International Conference On Opioids is designed to enlighten primary care physicians, pain specialists and other medical professionals with an interest in applied opioid pharmacology, with new data, essential information and best practices every medical professional needs to know when prescribing these powerful analgesics.

Known as the birthplace of the American Revolution, Boston enjoys world class education, arts, entertainment and sports. This modern compact city allows visitors to walk from the Longwood Medical area to the waterfront in less than an hour. From the brownstones of Beacon Hill to the lovely Boston Gardens and the Freedom Trail, Boston is a great destination to visit. Please join us.

Sign up now using the enclosed registration form or visit www.opioidconference.org.

Paul A. Sloan, MD  
Co-chair  
International Conference On Opioids™  
Editor-in-Chief  
Journal of Opioid Management®

Michael J. Brennan, MD  
Co-chair  
International Conference On Opioids™

The Journal of Opioid Management presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
Keynote Speakers

Kana Enomoto
Principal Deputy Administrator
Substance Abuse and Mental Health Services Administration (SAMHSA)

Addressing America's Opioid Crisis: How Practitioners Can Be Agents for Change

The opioid crisis is one of the most critical public health challenges of our time. A groundswell of action is needed, from every sector, to meet this crisis head on. Ms. Enomoto will discuss how SAMHSA is leading change at the national level to combat this growing problem, including how the 21st Century Cures Act and the Comprehensive Addiction Recovery Act of 2016 are shaping the federal response. She will focus on the critical part practitioners can play in the solution—including recommendations for using Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health as a resource for education and advocacy, and opportunities that exist for healthcare professionals to be change agents at every level—patient, health system, and at the local, community, state, and federal levels.

Sharon Walsh, PhD
Professor, Departments of Behavioral Science and Psychiatry
Director of the Center on Drug and Alcohol Research, University of Kentucky

Tackling the Opioid Epidemic with Science: Studies from the Laboratory and Clinic

The opioid epidemic continues to cause great morbidity and mortality among those who misuse opioids alone and in combination with other agents. Both the human laboratory and the clinic provide settings to explore various strategies that may improve these outcomes. Recent studies on novel pharmacotherapies for the treatment of opioid use disorder and potential adjunct treatments will be reviewed in this presentation. The presentation will describe both proof-of-concept studies and Phase III study outcomes. Data will be presented on novel formulations of buprenorphine that have just been recently marketed (i.e., the buprenorphine implant) and in the current pipeline (sustained release injectable formulations of buprenorphine) for opioid use disorder and for pain. Recent studies on the potential utility of agents from the cannabinoid class for use as adjuncts in the presence of opioids will also be reviewed. Finally, approved products and application for naloxone overdose prevention will be reviewed.
What is the Role of Opioid Abuse-Deterrent Formulations?

The ability to convert an extended opioid formulation into an immediate release opioid, or the ability to inject or snort an opioid, has contributed to an enormous public health crisis. It is imperative that we significantly reduce the level and risks of prescription opioids if opioids are to remain available for the treatment of pain. Abuse-deterrent formulations (ADFs) are an attempt to make opioids safer, but there has been tremendous opposition by payers to adopt the technology. This discussion will review the evidence and rationale for abuse deterrent formulations and where future development needs to go.

Dr. Lynn Webster is an expert in the field of pain management and is a leading voice in trying to help physicians safely treat pain patients.

---

**Keynote Speakers**

**Lynn R. Webster, MD, FACPM, FASAM**
Vice President of Scientific Affairs, PRA Health Sciences
Past President, American Academy of Pain Medicine (AAPM)

**What is the Role of Opioid Abuse-Deterrent Formulations?**

The ability to convert an extended opioid formulation into an immediate release opioid, or the ability to inject or snort an opioid, has contributed to an enormous public health crisis. It is imperative that we significantly reduce the level and risks of prescription opioids if opioids are to remain available for the treatment of pain. Abuse-deterrent formulations (ADFs) are an attempt to make opioids safer, but there has been tremendous opposition by payers to adopt the technology. This discussion will review the evidence and rationale for abuse deterrent formulations and where future development needs to go.

Dr. Lynn Webster is an expert in the field of pain management and is a leading voice in trying to help physicians safely treat pain patients.

---

**Special Presentation**

**Sunday, June 11, 2017, 6:30 pm - 8:00 pm**

*(Free Admission - Pre-Registration Requested)*

“*If Only*” is a short film co-written and co-produced by James Wahlberg and Michael Yebba with the purpose of building awareness of the ever-growing opiate addiction problem. It tells the story of two teenagers battling addiction to prescription opiates. “The film addresses one of the most serious health issues facing our society today. Addiction touches every culture, every family and ultimately every one of us,” Wahlberg said. “I'm grateful for the opportunity to create a project that informs, educates and leads viewers to recognize the warning signs of opioid abuse and to participate in a solution.”

Producer James Wahlberg is the middle child of the famous Boston family. Jim emerged from a tough upbringing in the streets of Dorchester, Massachusetts and has been Executive Director of the Mark Wahlberg Youth Foundation for more than a decade. The Foundation was created to improve the quality of life for inner city youth through a working partnership with other non-profit youth organizations. He has also been working in and around the field of addiction recovery for more than 25 years.

RSVP requested (no charge) Visit www.opioidconference.org/ifonly.html or call 781-899-2702 ext 103, or email michael_glynn@pnpco.com.
**CONFERENCE TOPICS**

**Clinical Application**

- **Pain Management**
  - Latest Clinical Applications of Opioid Therapies
  - Opioid Tapering, Rotation, Conversion and Dosing Strategies
  - Clinical Challenges in the Abuse Potential Assessment of CNS Active Drugs
  - Where to Draw the Line with Opioid Agonist Therapy
  - Pain Management in Opioid Addicted Patients
  - Opioids and Clinical Cannabis - An Overview
  - Evidence for Chronic Opioid Therapy
  - Pain Management for Cancer Survivors - Emerging and Evolving Challenges

- **Abuse Deterrent Formulations (ADFs)**
  - The Role of ADFs in Curbing Opioid Abuse - Can ADFs Reduce Opioid Abuse?

- **Compliance**
  - Implementing an Opioid Stewardship Program in a Healthcare System
  - Opioid Prescribing Guidelines
  - New Insights into Urine Drug Testing

**Addiction**

- **Prevention**
  - Reducing Community Prescribed Opioid Load as a Harm Reduction Strategy
  - Safe and Effective Prescribing of Controlled Substances to Prevent Addiction

- **Rescue/Treatment**
  - Addressing America's Opioid Crisis: How Practitioners Can Be Change Agents
  - Opioid Addiction: The Social Construction of an Epidemic
  - Weaning Off Opioids

**Legal**

- **Opioid Law**
  - Treating Pain Without Prosecution: Minimizing the Risk of Prescribing Opioids
  - Legal and Regulatory Implications of Prescribing Opioids in Everyday Practice
  - Your Name is on the Bottle: Current Opioid Prescribing Litigation Trends

**Pharmacology**

- **Pharmacology/Pharmacokinetics/Pharmacogenomics**
  - Pharmacokinetic Guidelines in Compliance Checks
  - Cutting-edge Pain Perception and Opioid Risk
  - Drug to Drug Interactions
  - Novel Pharmacology for the Treatment of Acute and Chronic Pain

**Basic Science**

- **Basic Science Research**
  - Tackling the Opioid Epidemic with Science: Studies from the Lab and Clinic
  - Translational Opioid and Pain Research
  - And More!

*Please see our website for a complete listing of presentations. Topics subject to change.*

Visit www.opioidconference.org for the latest schedule.
The landscape of opioid prescribing is complex and changing dramatically. Join us for this unique educational opportunity to learn from leaders in the field of opioids.

This intensive 2+ day program led by renowned specialists is designed to inform primary care physicians, pain specialists, pharmacists and other opioid prescribers in the uses, abuses and legal ramifications of opioid analgesics.

Learn to manage the complexities of opioid analgesics.

Acquire or refine your clinical skills including appropriate patient and opioid selection, monitoring, and reassessment. Come to a conference that will lay out the current landscape, explore the future and provide you with the information you need to know.

Why should you attend?

The conference features a full schedule of topics and speakers who will address all aspects of the medical use of opioids.

- Learn to reduce risk to your patients and your practice
- Hear about exciting developments in opioid neurology and pharmacology
- Learn the latest clinical concepts, ethics and legal aspects of opioid management from top medical professionals
- Gain an understanding of the newest methodologies for delivery of opioids
- Participate in constructive panel discussions and case studies with top professionals in opioid management
- Take advantage of meeting thought leaders and networking with colleagues

Register today!

Visit www.opioidconference.org for the latest schedule
Important Information and CME

Course Directors: Paul A. Sloan, MD, Michael J. Brennan, MD

CME Course Advisor: Daniel Alford, MD, MPH, FACP

Faculty Disclosure: Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices are being discussed.

Jointly Provided by Boston University School of Medicine and Weston Medical Publishing, LLC.

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Weston Medical Publishing, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

RN Credit: Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Weston Medical Publishing, LLC.

CPE Credit: The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ADA Support: Boston University School of Medicine and Weston Medical Publishing, LLC fully comply with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Michael Glynn at 781-899-2702 Ext. 103 by May 1, 2017 in order to receive services.

Cancellations: Should you be unable to attend, please inform us in writing prior to May 1, 2017 and a full refund less a 25% non-refundable administrative fee will be issued. No refunds or credits will be given for cancellations received on or after May 2, 2017. Substitutions of enrolled registrants must be made in writing. If for any reason this conference is canceled, the conference organizers and sponsors do not accept responsibility for covering airfare, hotel or other costs incurred by conference registrants. The speakers and agenda of this program are subject to change without notice due to unforeseen circumstances beyond the control of conference presenters.

Hotel Information: Please visit www.opioidconference.org for details.

** At the end of the six month subscription period you will receive an automatic renewal notice at the preferred rate.

Copyright 2017 Weston Medical Publishing, LLC All Rights Reserved 13216 Rev B. 034217
Registration Fee: $695 per person - Includes a six month subscription to Journal of Opioid Management (JOM)** - a $180 value

Early Registration Fee: $645 ends April 15, 2017 [Journal of Opioid Management subscribers receive an additional $50 discount off the registration fee above. Rates in USD]

Visit our website for Student/Resident/Nurse/PA/NP rates.

Mail to: ICOO, 470 Boston Post Rd., Suite 301, Weston, MA 02493, USA
Fax: 781-899-4900 Call: 800-743-7206 x108, 781-899-2702 (Outside US)

Register Online: www.opioidconference.org

Name of Attendee ____________________________________________

Title ______________________________________________________

Institution _________________________________________________

Address ___________________________________________________

City ___________________________ State _____ Zip_________

E-mail (Req'd) ____________________________________________

Are you a Journal of Opioid Management subscriber? Yes [ ] No [ ]

[ ] Subscribe me to JOM now (Add $311/yr., Special ICOO 2017 Rate)

Daytime Telephone Number (_____) __________________________

Payment Amount $__________________ [ ] Visa [ ] MC [ ] AMEX

Credit Card # _____________________________________________

Security Code (CCV) ___________ Exp. Date _________________

Name on Credit Card _______________________________________

Card Billing Address _______________________________________

Signature ________________________________________________
Sunday, June 11, 2017

8:15 am – 9:15 am
Addressing America’s Opioid Crisis: How Practitioners Can be Agents for Change
Kana Enomoto

9:15 am – 10:00 am
The Effect of Abuse-Deterrent Formulations and Immediate-Release Opioids on Abuse, Overdose and Death from Prescription Opioids
Richard Dart, MD, PhD; Dan Cohen; Paul Coplan, ScD

10:30 am – 11:15 am
Evidence for Chronic Opioid Therapy
Charles Argoff, MD

11:15 am – 11:30 am
Opiate Use and Over-Prescription in Post-Operative Patients
Eric Chen, MD, PhD

11:30 am – 12:30 pm
Improving Opioid Safety and Access to Quality Pain Care within the VA New England Healthcare System (VISN 1)
Julie Franklin, MD, MPH; Tu Ngo, PhD, MPH

1:30 pm – 2:15 pm
Looking Both Ways Before Crossing the Street: Assessing the Benefits and Risk of Opioids in COPD
Mellar P. Davis, MD

2:15 pm – 3:00 pm
MeDSS: A Data-Driven Decision Support Tool for Pain Management
Jaya Tripathi; Scott Weiner, MD, MPH

3:00 pm – 3:30 pm
Pain Patient Reported Outcomes as a Predictor of Healthcare Resource Utilization (HCRU) in Prostate Cancer Patients
Natalie Moryl, MD; Ali Bokhari; Alison Wiesenthal, MD

4:00 pm – 4:15 pm
KFL&A Public Health Action Plan on Opioids: Reducing the Community Opioid Load
Kieran Moore, MD, CCFP(EM); FCFP, MPH, DTM&H, FRCPC

4:15 pm – 4:30 pm
Summary/Overview of Opioid Management in Cancer Survivors
Paul A. Sloan, MD

5:00 pm – 6:00 pm
Top Three Posters Presented

Monday, June 12, 2017

8:00 am – 9:00 am
KEYNOTE: Tackling the Opioid Epidemic with Science: Studies from the Laboratory and Clinic
Sharon Walsh, PhD

9:00 am - 9:30 am
Quantitative Urine Drug Testing Offers Some Novel Insights
Amadeo Pesce, PhD, DABCC

10:00 am - 10:30 am
Tapering Opioids Safely
Paul A. Sloan, MD

10:30 am - 11:30 am
To Infinity and Beyond!
Safe and Effective Titration of Basal and Bolus Opioid Doses
Mary Lynn McPherson, PharmD, BCP; Kathryn Walker, PharmD, BCPS

11:30 am – 12:00 pm
Top Three Posters Presented

12:00 pm - 12:30 pm
Closing Keynote
TBA

12:30 pm
ICOO 2017 Conference Wrap Up